La cadena de opciones muestra datos clave de las opciones de acciones de CytomX Therapeutics a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para CytomX Therapeutics..

CytomX Therapeutics (NASDAQ:CTMX) Bolsa, Cadena de Opciones

CytomX Therapeutics

CytomX Therapeutics Inc is an oncology-focused biopharmaceutical company that is operating in the United States. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.

CytomX Therapeutics Inc

WIIM

PARA

Paramount Global shares are trading lower following mixed Q3 results.

Northland Capital Markets analyst Tim Savageaux maintains Lumentum Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LITE#NASDAQ">LITE</a>) with a Market Perform and raises the price target from $45 to $60.

News

Price Target

Analyst Ratings

LITE

Northland Capital Markets Maintains Market Perform on Lumentum Holdings, Raises Price Target to $60

Northland Capital Markets analyst Mike Grondahl maintains MoneyLion (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ML#NYSE">ML</a>) with a Outperform and raises the price target from $60 to $80.

Northland Capital Markets Maintains Outperform on MoneyLion, Raises Price Target to $80

Northland Capital Markets analyst Greg Gibas maintains Nerdy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NRDY#NYSE">NRDY</a>) with a Market Perform and lowers the price target from $3 to $2.

NRDY

Northland Capital Markets Maintains Market Perform on Nerdy, Lowers Price Target to $2

Northland Capital Markets analyst Mike Grondahl maintains Sezzle (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SEZL#NASDAQ">SEZL</a>) with a Outperform and raises the price target from $185 to $300.

SEZL

Northland Capital Markets Maintains Outperform on Sezzle, Raises Price Target to $300

U.S. stocks were higher, with the Dow Jones index gaining more than 200 points on Friday.
Shares of Sony Group Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SONY#NYSE">SONY</a>) rose sharply during Thursday's session after reporting better-than-expected second-quarter earnings and r<a href="https://www.benzinga.com/news/earnings/24/11/41841647/sonys-q2-profit-surges-on-gaming-and-sensor-gains-but-ps5-sales-decline-raises-full-year-outlook">aising FY24 revenue outlook</a>.
Sony Group reported fiscal second-quarter 2024 consolidated sales growth of 3% year-on-year to $19.44 billion (2.91 trillion Japanese yen), missing the analyst consensus estimate of $19.62 billion. EPS of $0.37 (55.74 yen) beat the analyst consensus estimate of $0.27.
Sony shares jumped 9.4% to $19.98 on Friday.
Here are some other big stocks recording gains in today's session.
<ul>
<li>Innodata Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INOD#NASDAQ">INOD</a>) shares surged 67.7% to $40.84.</li>
<li>Sezzle Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SEZL#NASDAQ">SEZL</a>) shares jumped 51.7% to $380.00 after the company reported a year-over-year increase in third-quarter financial results, raised its FY24 guidance, and issued FY25 adjusted EPS guidance above estimates.</li>
<li>Upstart Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UPST#NASDAQ">UPST</a>) surged 44% to $79.89 after the company reported better-than-expected quarterly financial results.</li>
<li>indie Semiconductor, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INDI#NASDAQ">INDI</a>) gained 43.3% to $4.9200 after the company reported better-than-expected third-quarter financial results.</li>
<li>Doximity, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOCS#NYSE">DOCS</a>) gained 37.8% to $59.87 following better-than-expected second-quarter financial results.</li>
<li>Fortrea Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTRE#NASDAQ">FTRE</a>) rose 32% to $23.82 after the company issued FY24 revenue guidance above estimates.</li>
<li>Axon Enterprise, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXON#NASDAQ">AXON</a>) gained 26.3% to $591.89 after the company reported better-than-expected third-quarter financial results and issued current-quarter revenue guidance above estimates.</li>
<li>Ubiquiti Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UI#NYSE">UI</a>) gained 20.4% to $314.49 following upbeat quarterly earnings.</li>
<li>Bloom Energy Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BE#NYSE">BE</a>) rose 19.8% to $12.78. The company announced a 20 MW utility deal with FPM Development and Baird maintained an Outperform rating on the stock.</li>
<li>Tempus AI, Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEM#NYSE">TEM</a>) gained 18.8% to $67.50.</li>
<li>AAON, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAON#NASDAQ">AAON</a>) shares rose 15.7% to $137.83 after the company reported better-than-expected quarterly financial results. Also, Baird raised its price target on the stock from $130 to $138 and maintained an Outperform rating.</li>
<li>Lumentum Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LITE#NASDAQ">LITE</a>) gained 14.4% to $84.25 after the company reported better-than-expected first-quarter financial results and issued second-quarter guidance above estimates.</li>
<li>Toast, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TOST#NYSE">TOST</a>) gained 13.3% to $37.00 after the company reported better-than-expected quarterly financial results.</li>
<li>Tesla, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) rose 8.3% to $321.66. The stock has continued to gain following the US presidential election.</li>
<li>SharkNinja, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SN#NYSE">SN</a>) gained 7.1% to $102.80.</li>
<li>Expedia Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXPE#NASDAQ">EXPE</a>) gained 5.8% to $184.24 after the company reported better-than-expected third-quarter adjusted EPS results. </li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/markets/24/11/41820056/how-to-earn-500-a-month-from-nvidia-stock-after-trump-win">How To Earn $500 A Month From Nvidia Stock After Trump Win</a></li>
</ul>

Intraday Update

Markets

Movers

Trading Ideas

AAON

AXON

DOCS

EXPE

FTRE

INDI

INOD

Sony Group Corporation American Depositary Shares

SONY

TOST

TSLA

UPST

Sony Posts Upbeat Earnings, Joins Tesla, Upstart, Doximity, Fortrea, Axon Enterprise And Other Big Stocks Moving Higher On Friday

Northland Capital Markets analyst Greg Gibas maintains GEO Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GEO#NYSE">GEO</a>) with a Outperform and raises the price target from $16 to $37.

Northland Capital Markets Maintains Outperform on GEO Group, Raises Price Target to $37

COIN

Coinbase shares are trading higher amid the election of President-Elect Trump as his policies could be favorable towards the crypto market.

Barclays analyst Mario Lu maintains Match Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MTCH#NASDAQ">MTCH</a>) with a Overweight and lowers the price target from $55 to $53.

MTCH

Barclays Maintains Overweight on Match Group, Lowers Price Target to $53

BBWI

Bath & Body Works shares are trading lower after Barclays downgraded the stock from Equal-Weight to Underweight and lowered its price target from $31 to $28.

Barclays analyst Andrew Mok maintains Tenet Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/THC#NYSE">THC</a>) with a Overweight and raises the price target from $171 to $190.

Barclays Maintains Overweight on Tenet Healthcare, Raises Price Target to $190

COST

Costco shares are trading higher after the company reported better-than-expected Q3 Financials.

Speculation has arisen regarding Charles Hoskinson, the co-founder of Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>) and Cardano (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/ada/usd">ADA</a>), potentially serving as a <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/41785767/bitcoins-future-under-president-elect-donald-trump-a-look-at-his-crypto-policies">cryptocurrency policy advisor</a> in the administration of president Donald Trump.
What Happened: This speculation comes on the heels of recent posts and statements from various figures within the crypto community, hinting at a possible alignment of interests between Hoskinson and the Trump campaign, particularly with Trump&#8217;s recent ventures into the cryptocurrency space.
The buzz started when Rick McCracken, a notable figure in the Cardano community, expressed <a href="https://x.com/TamaraHaasen/status/1854865475194294383">hope</a> on X (formerly Twitter) that the Trump-Vance administration might consider Hoskinson for such a role.
This suggestion was not made in a vacuum; Hoskinson has previously <a href="https://x.com/RobertKennedyJr/status/1780726997020508562">endorsed</a> Robert F. Kennedy Jr., who has since joined Trump&#8217;s team, indicating a potential pathway for dialogue or collaboration.
Hoskinson, known for his vocal criticism of the current administration&#8217;s crypto policies, has often highlighted the lack of regulatory clarity and what he perceives as an adversarial stance against the crypto industry. 
His endorsement of RFK Jr. was seen as a move towards supporting candidates who promise a change in policy direction, focusing on healing national divisions and promoting economic freedom through decentralized technologies.
The crypto community&#8217;s interest in Hoskinson&#8217;s potential advisory role stems from his deep involvement in blockchain technology and his advocacy for a regulatory environment that fosters innovation rather than stifling it. 
His insights could be pivotal, especially given Trump&#8217;s family&#8217;s recent forays into decentralized finance (DeFi) projects, signaling a more crypto-friendly stance from the former president.
However, the path to such an appointment isn&#8217;t without hurdles.
Hoskinson&#8217;s criticisms of both major political parties for their handling of crypto regulations suggest that any advisory role would come with the expectation of pushing for significant policy reforms.
This could mean navigating the complex political landscape where crypto regulations are concerned, balancing between innovation and security.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/events/digital-assets/ "><img loading="lazy" decoding="async" width="300" height="250" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/03/29155259/905735A6-57D3-4874-9AA1-75D037842DB3-2.gif" alt="Benzinga Future of Digital Assets conference" class="wp-image-270548" /></a></figure>
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/41851865/bitcoin-to-200000-ethereum-to-10000-and-crypto-market-cap-to-4x-by-end-of-2025-says-standard-chartered">Bitcoin To $200,000, Ethereum To $10,000 And Crypto Market Cap To 4X By End Of 2025, Says Standard Chartered</a>
The discussion emerges as Cardano&#8217;s native token ADA has reclaimed its position as the ninth-largest cryptocurrency overall, and the seventh-largest when excluding stablecoins like Tether (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">USDT</a>) and USDC (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">USDC</a>). 
The token has shown significant momentum, up 13% over the past 24 hours and 30% over the past 30 days, breaking above key technical resistance levels that have been closely watched by market analysts, <a href="https://x.com/cryptorecruitr/status/1854902966550942065">according</a> to a crypto analyst.
Technical analysis of ADA&#8217;s current movement shows parallels to previous market cycles, particularly in relation to Bitcoin halving events. 
Market data indicates ADA is currently trading approximately 201 days after the latest Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) halving, comparable to a similar breakout pattern observed in the previous cycle at 193 days post-halving.
The asset has demonstrated a notable separation from its 20-day moving average, currently showing a 14% divergence. 
Key resistance levels are identified at $0.47, aligned with the 50-week moving average, while analysts have outlined potential targets extending to $0.60-0.70 based on current pattern formations.
The timing of these speculations couldn&#8217;t be more intriguing, especially with the upcoming Benzinga&#8217;s <a href="https://www.benzinga.com/events/digital-assets/agenda/">Future of Digital Assets</a> event on Nov. 19. 
This event could serve as a platform for further discussions or announcements regarding the intersection of cryptocurrency and U.S. policy, potentially shedding light on how figures like Hoskinson might influence or be <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/41823388/the-trump-effect-a-deep-dive-into-how-the-crypto-landscape-will-change-in-2025-and-beyond">influenced by political decisions.</a>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/11/41849213/crypto-queen-ruja-ignatova-onecoins-4-billion-fraud-mastermind-is-alive-and-in-south-africa-german-police-suspects">&#8216;Crypto Queen&#8217; Ruja Ignatova, OneCoin&#8217;s $4 Billion Fraud Mastermind, Is Alive And In South Africa, German Police Suspects</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$ADA

$BTC

$ETH

$USDC

$USDT

Cardano Up 13% As Speculation Around Charles Hoskinson As Trump Crypto Policy Advisor Bubbles

Barclays analyst Andrew Mok maintains HCA Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HCA#NYSE">HCA</a>) with a Overweight and lowers the price target from $396 to $392.

Barclays Maintains Overweight on HCA Healthcare, Lowers Price Target to $392

LFMD

LifeMD shares are trading higher after the company reported better-than-expected Q3 adjusted EPS results.

Rumors

AUTL

Watching Autolus Therapeutics; Shares Spike Higher As Traders Circulate Aucatzyl Is Now FDA Approved As A Treatment For Adults With Acute Lymphoblastic Leukemia

Barclays analyst Tim Long maintains Motorola Solns (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MSI#NYSE">MSI</a>) with a Overweight and raises the price target from $467 to $529.

Barclays Maintains Overweight on Motorola Solns, Raises Price Target to $529

The S&amp;P 500 index surged past the 6,000-point milestone, setting fresh record highs, and small-cap stocks are poised for their best weekly performance since April 2024 as investor optimism surrounding the &#8220;Trump trade&#8221; continued to fuel a strong risk-on sentiment by the end of a <a href="https://www.benzinga.com/markets">wild week in the market</a>. 
All major U.S. indices posted modest gains in midday trading, with the Dow Jones Industrial Average leading slightly, soaring beyond the 44,000-point mark. The blue-chip index is set for its best weekly performance in over a year.
Friday's rise in the S&amp;P 500 was powered by the utilities and real estate sectors, which had lagged post-election. Tech stocks took a breather following Thursday's rally.
Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) surged 7%, pushing its weekly gains beyond 27% and propelling its market cap past $1 trillion. 
This move now places every "Magnificent Seven" tech stock in the trillion-dollar club, with the group's combined market cap topping $17 trillion.
Treasury yields held steady, while the dollar strengthened in response to the Federal Reserve's Thursday 25-basis-point rate <a href="https://www.benzinga.com/economics/macro-economic-events/24/11/41823887/powell-dismisses-talk-of-resignation-after-trump-victory-says-policy-is-still-res">cut to 4.5%-4.75%</a>.
Gold softened, eyeing its worst week since late May, as both silver and oil dropped over 2% on the day. Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) edged up 0.8%, extending its weekly gains to over 11%, marking its best week since July.
<h3 class="wp-block-heading">Friday&#8217;s Performance In Major US Indices, ETFs</h3>
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Major Indices</td>
<td>Price</td>
<td>1-day %chg</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>43,993.21</td>
<td>0.6%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>5,998.81</td>
<td>0.4%</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>2,389.50</td>
<td>0.3%</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>21,124.53</td>
<td>0.1%</td>
</tr>
</tbody>
</table>
<figcaption class="wp-element-caption">Updated at 1:05 p.m. ET</figcaption></figure>
According to <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent110824&amp;t=be2bearmibe3na1">Benzinga Pro</a> data:
<ul>
<li>The&nbsp;SPDR S&amp;P 500 ETF Trust&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) rose 0.4% to $598.17.</li>
<li>The&nbsp;SPDR Dow Jones Industrial Average&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIA#NYSE">DIA</a>)&nbsp;rose 0.6% to $439.89.</li>
<li>The tech-heavy Invesco QQQ Trust Series (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>) inched 0.1% higher to $514.10.</li>
<li>The iShares Russell 2000 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IWM#NYSE">IWM</a>) rose 0.3% to $237.08.</li>
<li>The Utilities Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLU#NYSE">XLU</a>) outperformed, rising 1.8%. The Materials Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLB#NYSE">XLB</a>) lagged, down 1%.</li>
</ul>
<h3 class="wp-block-heading">Friday&#8217;s Stock Movers</h3>
Stocks reacting to earnings reports were: 
<ul>
<li>NRG Energy Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NRG#NYSE">NRG</a>), up 0.5%, </li>
<li>Ubiquiti Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UI#NYSE">UI</a>), up 21%</li>
<li>Arista Networks Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANET#NASDAQ">ANET</a>), down 7%, </li>
<li>Airbnb Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABNB#NASDAQ">ABNB</a>), down 7.5%, </li>
<li>Motorola Solutions Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MSI#NYSE">MSI</a>), up 6.7%, </li>
<li>EOG Resources Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EOG#NYSE">EOG</a>), up 5.9%, </li>
<li>Fortinet Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTNT#NASDAQ">FTNT</a>), up over 9%, </li>
<li>The Trade Desk Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTD#NASDAQ">TTD</a>), down over 4%, </li>
<li>Monster Beverage Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNST#NASDAQ">MNST</a>), up by 0.5%, </li>
<li>Axon Enterprise Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXON#NASDAQ">AXON</a>), up 25%, </li>
<li>Block Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SQ#NYSE">SQ</a>), down 4.4%, </li>
<li>Cloudfare Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NET#NYSE">NET</a>), down 6.2%, </li>
<li>Corpay Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CPAY#NYSE">CPAY</a>), up 6%, </li>
<li>Expedia Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EXPE#NYSE">EXPE</a>), up over 6%, </li>
<li>Toast Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TOST#NYSE">TOST</a>), up 13%, </li>
<li>Pinterest Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PINS#NYSE">PINS</a>), down 17%, </li>
<li>DraftKings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DKNG#NASDAQ">DKNG</a>), up 1.7%, </li>
<li>Insulet Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PODD#NASDAQ">PODD</a>), up 12%, </li>
<li>News Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NWS#NASDAQ">NWS</a>), up 3.6%, </li>
</ul>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/economics/macro-economic-events/24/11/41848568/us-consumer-sentiment-rises-more-than-predicted-to-6-month-highs-inflation-expectations-hit-4-year-low">US Consumer Sentiment Rises More Than Predicted To 6-Month Highs, Inflation Expectations Hit 4-Year Low</a></li>
</ul>
Illustration created using artificial intelligence via Midjourney.

Equities

Sector ETFs

ETFs

ABNB

ANET

CPAY

SPDR Dow Jones Industrial Average ETF Trust

DKNG

FTNT

MNST

PINS

PODD

S&P 500 Breaks 6,000 Points, Dow Soars Above 44,000, Small Caps Eye Strongest Week In 4 Years, Tesla Hits $1 Trillion: What's Driving Markets Friday?

ATHA

Althira Pharma shares are trading lower after the company reported worse-than-expected Q3 EPS results.

Barclays analyst Jared Shaw maintains First Horizon (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FHN#NYSE">FHN</a>) with a Overweight and raises the price target from $21 to $23.

Barclays Maintains Overweight on First Horizon, Raises Price Target to $23

Warning: CTMX is at high risk of performing badly

CytomX Q3 2024 Earnings Preview

Reports Q3 revenue $33.43M, consensus $17.61M. "We are encouraged by the progress during Q3 across our clinical pipeline including the ongoing Phas...

CytomX Therapeutics reports Q3 EPS 7c, consensus (17c)

CytomX Therapeutics Inc. ( ($CTMX) ) has released its Q3 earnings. Here is a breakdown of the information CytomX Therapeutics Inc. presented to its...

CytomX Therapeutics Reports Q3 Progress and Growth

CytomX Therapeutics, Inc. (CTMX) Q3 2024 Earnings Call Transcript

Piper Sandler lowered the firm's price target on CytomX Therapeutics (CTMX) to $3.25 from $3.50 and keeps an Overweight rating on the shares follow...

CytomX Therapeutics price target lowered to $3.25 from $3.50 at Piper Sandler

CTMX

Opinion

Press Releases

Biotech Advances in 2024: Innovative Treatments Aim to Boost Pancreatic Cancer Survival Rates

Health Care

Management

CytomX Therapeutics Promotes Chris Ogden to Chief Financial Officer

CytomX Therapeutics to Present at the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference

CytomX Therapeutics to Report Second Quarter 2024 Financial Results on August 8, 2024

Earnings

CytomX Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

CytomX Therapeutics to Present at Upcoming September Investor Conferences

CytomX Therapeutics Announces First Patient Dosed with CX-801, a Dually-Masked Interferon-Alpha 2b PROBODY®, in a Phase 1 Study in Patients with Solid Tumors

CytomX Therapeutics to Report Third Quarter 2024 Financial Results on November 7, 2024

CytomX Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

BNTX

FGEN

ONCY

TSX:ONC

VSTM

Agenus

Aileron Therapeutics, Inc. - Common Stock

Aileron Therapeutics

ALX Oncology Holdings Inc. - Common Stock

ALX Oncology Holdings

Armata Pharmaceuticals, Inc. Common Stock

Armata Pharmaceuticals

Aerovate Therapeutics, Inc. - Common Stock

Aerovate Therapeutics

Biodexa Pharmaceuticals plc - American Depositary Shares

Biodexa Pharmaceuticals

bluebird bio

BeyondSpring

Celularity

Cellectar Biosciences, Inc. - Common Stock

Cellectar Biosciences

Chimerix

Connect Biopharma Holdings Limited - American Depositary Shares

Connect Biopharma Hldgs

DBV Technologies S.A. - American Depositary Shares

DBV Technologies

Precision BioSciences, Inc. - Common Stock

Precision BioSciences

IO Biotech

MAIA Biotechnology

Metagenomi

MediciNova

Protalix BioTherapeutics, Inc. (DE) Common Stock

Protalix BioTherapeutics

Prelude Therapeutics Incorporated - Common Stock

Prelude Therapeutics

Quince Therapeutics

SELLAS Life Sciences Group, Inc. - Common Stock

SELLAS Life Sciences Gr

Spero Therapeutics

Syros Pharmaceuticals, Inc. - Common Stock

Syros Pharmaceuticals

Vistagen Therapeutics, Inc. - Common Stock

Comments

CytomX Therapeutics

CytomX Therapeutics (CTMX) Opciones

CytomX Therapeutics (NASDAQ:CTMX) Bolsa, Cadena de Opciones

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL